BioNTech SE completed the acquisition of Neon Therapeutics, Inc. from Third Rock Ventures, LLC and others.
Mitchell S. Bloom, James A. Matarese and Lillian Kim of Goodwin Procter LLP acted as legal advisors to Neon and Ondra LLP acted as financial advisor to Neon. Paul Claydon, Brian K. Rosenzweig, Matthew T. Gehl and Jack S. Bodner of Covington & Burling LLP acted as legal advisors to BioNTech SE. Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisor to Neon Therapeutics, Inc. Jochen Dieselhorst and Peter Versteegen of Freshfields Bruckhaus Deringer (Germany) acted as legal advisors to BioNTech SE. Innisfree M&A Inc. acted as proxy solicitor to Neon Therapeutics and Neon would pay a fee of approximately $15,000 plus expenses. Duff & Phelps, LLC provided a fairness opinion and acted as financial advisor to Neon's board of directors in connection with the transaction. Neon agreed to pay Duff & Phelps a fee of $250,000 for its services, $125,000 of which became payable upon signing the engagement letter and $125,000 became payable upon Duff & Phelps informing the Neon Board that it was prepared to deliver its opinion. The Bank of New York Mellon Corporation (NYSE:BK) acted as depositary to BioNTech.
BioNTech SE (NasdaqGS:BNTX) completed the acquisition of Neon Therapeutics, Inc. (NasdaqGS:NTGN) from Third Rock Ventures, LLC and others on May 6, 2020. As a result of the transaction, Neon will operate under the name of BioNTech US Inc. and serve as BioNTech's U.S. headquarters. As of May 7, 2020, Neon's common stock will no longer be available for trading.